Acotec Scientific IPO: Valuation Insights
Our base-case DCF valuation is HK$21.65 per share, which is a -6% downside to the mid-point of the IPO price range. Consequently, we think the...
317 Views
Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic
Our DCF valuation offers a price per share of HK$182.78 which is 6.9% higher than the upper end of the company’s indicative IPO price range of...
328 Views
Shanghai HeartCare Medical IPO: Valuation Insights
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.
594 Views
Heartcare (心玮医疗) IPO: Decent Upside Barring Negative Lawsuit Outcomes
We provide an update for HeartCare's book building. We think the upside is substantial barring negative outcomes from the legal proceedings with...
325 Views
Shanghai HeartCare (心玮医疗) Pre-IPO: Thoughts on Valuation
We forecast the sales of HeartCare's four key products, namely Captor, Intracranial Catheter, LAA Occluder, and embolic coil, and also provide an...
410 Views